Der p2A20 DNA vaccine attenuates allergic inflammation in mice with allergic rhinitis.
Mol Med Rep
; 20(6): 4925-4932, 2019 Dec.
Article
en En
| MEDLINE
| ID: mdl-31638224
ABSTRACT
Allergic rhinitis (AR) is a common disease that requires more convenient, safe and effective antigenspecific immunotherapies. The present study aimed to investigate the therapeutic effect of intranasal administration of a eukaryotic expression vector coexpressing Der p2 and A20 protein (pVAX1Der p2A20) on mice with allergic rhinitis. The pVAX1Der p2A20 vaccine was prepared and encapsulated into poly(Llactidecoglycolide) (PLGA) nanoparticles. An allergic rhinitis Balb/c mouse model was established through intraperitoneal sensitization with recombinant Der p2 and cholera toxin followed by intranasal challenge with recombinant Der p2. The treatment effect of the DNA vaccine on nasal allergic inflammation was evaluated, and serum IgE, sIgE, IgG and cytokine levels were determined by ELISA. The percentage of CD4+CD25+Foxp3+Tregs in the spleen was detected by flow cytometry. The DNA vaccine coexpressing Der p2 and A20 was successfully constructed and encapsulated into PLGA nanoparticles. Der p2A20 DNA vaccine intranasal administration markedly ameliorated Der p2induced nasal allergic inflammation. The serum Der p2specific IgE, IL4 and IL13 expression levels were inhibited, while the Der p2specific IgG1, IgG2a and IFNγ expression levels in the serum and splenic CD4+CD25+Foxp3+Treg population were significantly increased after Der p2A20 DNA vaccine treatment. These results indicated that the Der p2A20 DNA vaccine alleviates nasal allergic inflammation and promotes splenic Treg population in mice with allergic rhinitis.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vacunas de ADN
/
Rinitis Alérgica
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Mol Med Rep
Año:
2019
Tipo del documento:
Article